【DPHARMA 7148 交流专区】（前名 CCMDBIO）

icy97

Type	Announcement
Subject	OTHERS
Description	ACCEPTANCE OF CREDIT FACILITIES FROM OCBC BANK (MALAYSIA) BERHAD OF UP TO RM19.55 MILLION
The Board of Directors of CCM Duopharma Biotech Berhad (“CCMD”) wishes to announce that its wholly owned subsidiary, Duopharma (M) Sdn Bhd (“DMSB”) has entered and executed a Credit Facilities Agreement with OCBC Bank (Malaysia) Berhad (“OCBC”) for an additional amount RM10 million on 6 July 2017, based on terms and conditions as contained in the Bank’s offer letter dated 27 April 2017. Please refer attachment below.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/5479069

Attachments Bursa Announcement - Acceptance of CF from OCBC Bank of up to RM19.55 million (Final).doc

icy97

icy97 发表于 26-1-2017 04:26 AM
CCM Duopharma获3亿合约 为政府医院提供人胰岛素
By Sulhi Azman / theedgemarkets.com   | January 25, 2017 : 4:18 PM MYT

（吉隆坡25日讯）CCM Duopharma Biotech Bhd宣布，独资子公司CCM Pharmaceuticals私 ...

马化学药业获卫生部3亿合约

（吉隆坡22日讯）马化学药业（CCMDBIO，7148，主板消费品组）独资子公司正式与卫生部、产品制造商签署一项供应与交付人类胰岛素合约，供应与交付合约总值3亿零4万令吉。

上述供应及交付人类胰岛素合约，由政府、产品制造商-Biocon有限公司及后者授权分销商／重新销售商——马化学药剂有限公司（CCMP）正式签署，后者为公司独资子公司。

上述合约为期3年，从2016年12月2日开始至2019年12月1日，惟政府拥有将合约延长另外2年的权利，惟需要涉及各造所同意条件。

文章来源：
星洲日报‧财经‧2017.08.23

Type	Announcement
Subject	OTHERS
Description	ACCEPTANCE OF TENDER OFFER (HEREINAFTER REFERRED TO AS LETTER OF AWARD) FOR THE SUPPLY OF HUMAN INSULIN FORMULATIONS (HEREINAFTER REFERRED TO AS PRODUCTS) UNDER MINISTRY OF HEALTHS (MOH) OFF-TAKE AGREEMENT PROGRAM
We refer to our announcements dated 25 January 2017 and 26 January 2017 on the above and are pleased to announce that the Agreement for the Supply and Delivery of Human Insulin Products (hereinafter referred to as “Agreement”) between the Government of Malaysia (“Government”), Biocon Sdn Bhd (“Biocon”) as the manufacturer and CCM Pharmaceuticals Sdn Bhd (“CCMP”) as Biocon’s Authorised Distributor / Reseller had been formally executed. The Agreement entered into by the Government, Biocon and CCMP for the supply of the Products is in the ordinary course of business of CCM Duopharma Biotech Berhad’s (CCMD) Group. The full details of the announcement is per the attached file. This announcement is dated 22 August 2017.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/5521329

Attachments Announcement - Biocon Government CCMP Execution of Off-Take Areement (F).docx

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Jun 2017

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Jun 2017	30 Jun 2016	30 Jun 2017	30 Jun 2016
		$$'000	$$'000	$$'000	$$'000

1	Revenue	117,049	79,135	240,355	158,605
2	Profit/(loss) before tax	12,642	7,723	24,764	17,664
3	Profit/(loss) for the period	9,641	3,941	19,205	11,769
4	Profit/(loss) attributable to ordinary equity holders of the parent	9,653	4,503	19,217	12,346
5	Basic earnings/(loss) per share (Subunit)	3.46	1.41	6.88	4.22
6	Proposed/Declared dividend per share (Subunit)	2.50	2.50	2.50	2.50
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	1.6600		1.6300

icy97

EX-date	17 Oct 2017
Entitlement date	20 Oct 2017
Entitlement time	05:00 PM
Entitlement subject	Interim Dividend
Entitlement description	Interim Dividend of 2.5 sen per share
Period of interest payment	to
Financial Year End	31 Dec 2017
Share transfer book & register of members will be	to   closed from (both dates inclusive) for the purpose of determining the entitlement
Registrar or Service Provider name, address, telephone no	TRICOR INVESTOR & ISSUING HOUSE SERVICES SDN BHDUnit 32-01, Level 32, Tower A,Vertical Business Suite, Avenue 3, Bangsar South,No. 8, Jalan Kerinchi59200Kuala LumpurTel:0327839299Fax:0327839222
Payment date	10 Nov 2017
a.Securities transferred into the Depositor's Securities Account before 4:00 pm in respect of transfers	20 Oct 2017
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit
c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)
Entitlement indicator	Currency
Currency	Malaysian Ringgit (MYR)
Entitlement in Currency	0.025

icy97

Notice of Interest Sub. S-hldr (Section 137 of CA 2016)

CCM DUOPHARMA BIOTECH BERHAD

Particulars of Substantial Securities Holder

Name	CHEMICAL COMPANY OF MALAYSIA BERHAD
Address	13TH FLOOR, MENARA PNB 201-A, JALAN TUN RAZAK KUALA LUMPUR 50400 Wilayah Persekutuan Malaysia.
Company No.	5136-T
Nationality/Country of incorporation	Malaysia
Descriptions (Class)	Ordinary Shares
Name & address of registered holder	Chemical Company of Malaysia Berhad13th Floor, Menara PNB201-A, Jalan Tun Razak50400 Kuala Lumpur

Date interest acquired & no of securities acquired
Date interest acquired	25 Sep 2017
No of securities	204,665,784
Circumstances by reason of which Securities Holder has interest	Settlement for amount owing by CCM Marketing Sdn Bhd (CCMM) to Chemical Company of Malaysia Berhad (CCMB) of RM204,665,784 by way of transfer to CCMB 204,665,784 ordinary shares in the share capital of CCM Duopharma Biotech Berhad (CCMD) owned by CCMM, a wholly owned subsidiary of CCMB, in CCMD, pursuant to the Debt Settlement Agreement entered into between CCMM and CCMB dated 11 August 2017. Upon the fulfillment of all the conditions precedent of the Debt Settlement Agreement dated 11 August 2017 including the receipt of the approval of the SC exempting CCMB from the obligation to undertake the Mandatory Offer 1 vide its letter dated 29 August 2017, the transfer of 204,665,784 CCMD Shares from CCMM to CCMB arising from the Debt Settlement Agreement  has been completed on 25 September 2017, hence increasing the  direct shareholding of CCMB in CCMD from zero to 73.37%
Nature of interest	Direct Interest
Total no of securities after change
Direct (units)	204,665,784
Direct (%)	73.37
Indirect/deemed interest (units)
Indirect/deemed interest (%)
Date of notice	25 Sep 2017
Date notice received by Listed Issuer	25 Sep 2017

哭哭鸟

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Sep 2017

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Sep 2017	30 Sep 2016	30 Sep 2017	30 Sep 2016
		$$'000	$$'000	$$'000	$$'000

1	Revenue	115,379	80,302	355,734	238,907
2	Profit/(loss) before tax	14,207	7,516	38,971	25,180
3	Profit/(loss) for the period	11,127	6,226	30,332	17,995
4	Profit/(loss) attributable to ordinary equity holders of the parent	11,405	6,341	30,622	18,687
5	Basic earnings/(loss) per share (Subunit)	3.99	2.23	10.87	6.45
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	1.7000		1.6300

icy97

Type	Announcement
Subject	OTHERS
Description	LEONARD ARIFF MANDATED TO SPEARHEAD CCMD AS GROUP MANAGING DIRECTOR
We attach herewith a copy of the press release dated 4 December 2017. This announcement is dated 4 December 2017

http://www.bursamalaysia.com/market/listed-companies/company-announcements/5625213

Attachments Press Release CCMD Appoints GMD.docx

icy97

CEO转任董事经理．马化学药业战略不变

（吉隆坡5日讯）马化学药业（CCMDBIO，7148，主板消费品组）首席执行员李奥纳阿里夫将转任董事经理一职，让业务分拆后管理团队豁然开朗，达证券相信这将确保集团在2022年崛起为东盟前5大仿制药集团战略路线不变，对未来发展是一大利多。

达证券说，李奥纳阿里夫自2008年掌权以来，已积极通过和韩国P a n G e n生物科技有限公司和印度Biocon有限公司等全球制药公司结盟，并崛起成为国内最大红血球生成素（Erythropoietin）和胰岛素（Insulin）制造商。

马化学药业是在2015年宣布，放眼生产更多仿制药产品来提高营业额和捍卫赚益，以稀释本地和东南亚市场竞争激烈的学名药市场影响。

达证券说，除了盈利增长潜能和可观的周息率外，马化学药业进军高价利基的治疗产品前景看俏，因此维持其“买进”评级，目标价为2令吉70仙。



文章来源：
星洲日报‧财经‧2017.12.06

icy97

马化工药业赢1.56亿合约

2017年12月24日
（吉隆坡23日讯）马化工药业（CCMDBIO，7148，主板消费产品股）独资子公司Duopharma（大马）私人有限公司获得药品及非药品供应合约，价值大约1.56亿令吉。

马化工药业向交易所报备，Duopharma获得发马（PHARMA，7081，主板贸服股）旗下发马物流私人有限公司颁发合约，将提供产品给政府医院、诊所及其他中心。

这项供应合约的有效期为今年12月1日至2019年11月30日。【e南洋】

Type	Announcement
Subject	OTHERS
Description	CONTRACT FOR THE SUPPLY OF PHARMACEUTICAL AND/OR NON-PHARMACEUTICAL PRODUCTS TO HOSPITALS, CLINICS AND OTHERS UNDER THE GOVERNMENT OF MALAYSIA
We are pleased to announce that our wholly owned subsidiary company of CCM Duopharma Biotech Berhad ("the Company"), Duopharma (M) Sdn. Bhd. ("DMSB") has received and accepted a Letter of Offer from Pharmaniaga Logistics Sdn. Bhd. ("PLSB") to supply pharmaceuticals and/or non-pharmaceuticals products (“Products”) as listed in the Letter of Offer to hospitals, clinics and others under the Government of Malaysia (“Contract”). The acceptance of the Contract from PLSB for the supply of the Products is in the ordinary course of business of the Company. The full details of the announcement is per the attached file. This announcement is dated 22 December 2017.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/5645541

Attachments Announcement - Contract for Supply of Pharma and Non Pharma Products under the Govt fo Malaysia.docx

icy97

[tr][/tr]

Date of change	28 Dec 2017
Name	DATO' NORMALA BINTI ABDUL SAMAD
Age	55
Gender	Female
Nationality	Malaysia
Designation	Chairman
Directorate	Non Independent and Non Executive
Type of change	Resignation
Reason	The completion of the corporate exercise undertaken by Chemical Company of Malaysia Berhad (CCMB) in respect of the following, as announced to Bursa Malaysia on 2 August 2017, 4 August 2017, 11 August 2017, 30 August 2017, 25 September 2017, 3 October 2017, 13 October 2017, 28 November 2017, 22 December 2017 and 26 December 2017 on:-(I)  Proposed Placement of up to 10% of the Issued Share Capital of CCMB (excluding Treasury Shares)(Proposed Placement); (II)  Proposed Distribution of the Entire Shareholding in CCM Duopharma Biotech Berhad (CCMD) (Proposed Distribution) to the Shareholders of CCMB by way of a Reduction of the Paid Up Capital of CCMB Pursuant to Section 116 of the Companies Act 2016 (Proposed Distribution and Capital Reduction); and(III) Proposed Share Consolidation of Every 3 Existing Ordinary Shares in CCMB ("CCMB Share(s)" or  Share(s)") into 1 Ordinary Share in CCMB ("Consolidated Share(s)") ("Proposed Share Consolidation")
Details of any disagreement that he/she has with the Board of Directors	No
Whether there are any matters that need to be brought to the attention of shareholders	No
Qualifications	(i) Master of Business Administration Majoring in Human Resource, Nottingham Trent University, United Kingdom (ii) Bachelor of Administration Management, Paramount University of Technology, United Kingdom (iii) Diploma in Professional Safety Management, Construction and Industrial Safety Training Centre (CONSIST), Australia (iv) Diploma in Human Resource Administration, Malaysian Institute of Personnel Management (MIPM) (v) Certificate in Personnel Management, Malaysian Institute of Personnel Management (MIPM) (vi) Certificate in Safety & Health Officer, National Institute of Safety & Health (NIOSH)
Working experience and occupation	Dato' Normala is currently the Chairman of Chemical Company of Malaysia Berhad and a Member of Parliament for Pasir Gudang Constituency in Johor since 2013. She is also a Committee member of the International Bureau of Wanita UMNO Malaysia and a member of the Wanita UMNO for Johor State. In addition, she is the Chief of the UMNO's Womens Wing for Pasir Gudang Division.Before her foray into politics, Dato' Normala has accumulated over 32 years of experience in Human Resources and Workers Safety and Health. She began her career in Human Resource in 1981 with Pan Century Edible Oils Sdn. Bhd., Pasir Gudang and progressed to the position as Head of Human Resources in 1992 at Pan Century Oleochemicals Sdn. Bhd. She later joined Grand Bank Yachts Sdn. Bhd. in 1995 as a Human Resources Manager and resigned in 2013.Dato' Normala is very active in non-governmental organisations and holds various positions such as Chairman of Mimbar Permuafakatan Ibu Bapa Malaysia (MAPIM), Pasir Gudang and Supreme Council Member of MAPIM (National Level), Chairman of the Womens Bureau of Drug Prevention Association of Malaysia (PEMADAM) Johor, Chairman of the Development Council of Women & Family for Pasir Gudang, Chairman of Perkumpulan Wanita (PERWANI) Parliament Pasir Gudang, Chairman and Founder of Koperasi Seri Cempaka Pasir Gudang Berhad and Chairman of the Advisory Board of Community College Pasir Gudang.She was the former Deputy Chairman of the Federation of Malaysian Manufacturers (FMM), Johor Branch since 2000 and also chaired various committees on FMM. She was also the former Deputy Chairman of Human Resources Officers Group for Pasir Gudang Industrial Area, former Deputy Chairman of Malaysian Employers Federation Johor, Honorary Secretary of Malaysian Association of Safety and Health Officers, former Panel Member of Appeal Cases Committee for Court of Appeals SOCSO cases and former Panel Member of Industrial Court Malaysia.

icy97

Date of change	28 Dec 2017
Name	ENCIK LEONARD ARIFF BIN ABDUL SHATAR
Age	53
Gender	Male
Nationality	Malaysia
Designation	Managing Director
Directorate	Executive
Type of change	Appointment
Qualifications	1) LL.B, Monash University, Melbourne, Australia2) Bachelor of Economics, Monash University, Melbourne, Australia
Working experience and occupation	Leonard Ariff has been appointed as the Chief Executive Officer of CCM Duopharma Biotech Berhad since 1 January 2008 until to-date. On 9 January 2015, he was appointed the Group Managing Director of Chemical Company of Malaysia Berhad, a position he carries until to-date. He is also the Chief Executive Officer of the Pharmaceuticals Division of the CCM Group following an internal reorganisation of the CCM Group in January 2016. Prior to that, he was the Director of the Pharmaceuticals Division since January 2008.Leonard Ariff started his career in 1988 in various capacities in the legal profession before joining the CCM Group in 1990, where his main responsibilities were in business development and business management at  CCM Chemicals Sdn. Bhd. In 2000, he assumed the position of Managing Director of Usaha Pharma (M) Sdn. Bhd. (formerly known as Prima Health Pharmacy (Retail) Sdn. Bhd.), CCM's pharmaceuticals retail arm. He later joined ICI Paints Malaysia Sdn. Bhd. in 2003 as the General Manager and was subsequently appointed as the Managing Director in 2005 until 2007, before re-joining the CCM Group in 2008. He was also the Director of CCM's Chemicals Division from October 2014 until December 2015.He holds directorships on the boards of Orica-CCM Energy Systems Sdn. Bhd., an associate company of Chemical Company of Malaysia Berhad and PanGen Biotech Inc. (Korea). He also acts in an advisory capacity at the International Medical University School of Pharmacy, Chair of the School of Business Advisory Board at Monash University Malaysia, Industrial and Community Advisory panel of Institute for Research in Molecular Medicine (INFORMM) at Universiti Sains Malaysia, and Committee Member of Good Governance for Medicines in the Ministry of Health, Malaysia. He is also a member of the Malaysian National Biotech Advisory Board.
Directorships in public companies and listed issuers (if any)	Chemical Company of Malaysia Berhad

icy97

Date of change	28 Dec 2017
Name	TAN SRI SITI SA'DIAH BINTI SH BAKIR
Age	65
Gender	Female
Nationality	Malaysia
Type of change	Redesignation
Previous Position	Independent Director
New Position	Chairman
Directorate	Non Independent and Non Executive
Qualifications	1. Master of Business Administration, Henley Business School, University of Reading, United Kingdom2. Bachelor in Economics, University of Malaya
Working experience and occupation	Tan Sri Siti Sa'diah binti Sh Bakir is an Independent Non-Executive Director of KPJ, redesignated on 1 May 2015 from Non-Independent, Non-Executive Director. Tan Sri served as the Managing Director of KPJ from 1 March 1993 until her retirement on 31 December 2012.From 1 January 2013 until 31 December 2014, she served as KPJs Corporate Advisor. She was the Chairman and Pro-Chancellor of KPJ Healthcare University College (KPJUC) between 1 August 2011 to 31 December 2016.Her career with Johor Corporation (JCorp) commenced in 1974 and she has been directly involved in JCorpsHealthcare Division since 1978. She was appointed as the Chief Executive of Kumpulan Perubatan (Johor) Sdn. Bhd (KPJSB), from 1989 until the listing of KPJ in November 1994.Committed to promoting excellence in healthcare, Tan Sri is the President of Malaysian Society for Quality in Health (MSQH), the national accreditation body for healthcare services, elected since its inception in 1997 to date. She sits on many other councils and committees at the national level, including as a member of the Academic Committee of the Razak School of Government (RSOG). She also sits on several University Committees, including Universiti Malaya and University of Reading Malaysia. In June 2016, she was appointed as the Chairman of Universiti Utara Malaysia, an eminent management university in Malaysia.In 2010, Tan Sri was named the CEO of The Year 2009 by the New Straits Times Press and the American Express. She has received many more awards and accolades from 2011 to 2015, due to her contributions to the healthcare industry in Malaysia. She launched her biography entitled Siti Sadiah: Driven by Vision, Mission and Passion, penned by Professor Rokiah Talib, Penerbitan Universiti Kebangsaan Malaysia in 2013.

icy97

Notice of Interest Sub. S-hldr (Section 137 of CA 2016)

CCM DUOPHARMA BIOTECH BERHAD

Particulars of Substantial Securities Holder

Name	PERMODALAN NASIONAL BERHAD
Address	TINGKAT 4, BALAI PNB, 201-A, JALAN TUN RAZAK, 50400 KUALA LUMPUR. KUALA LUMPUR 50400 Wilayah Persekutuan Malaysia.
Company No.	038218-X
Nationality/Country of incorporation	Malaysia
Descriptions (Class)	ORDINARY SHARES
Name & address of registered holder	PERMODALAN NASIONAL BERHADTINGKAT 4, BALAI PNB, 201-A, JALAN TUN RAZAK,50400 KUALA LUMPUR.

Date interest acquired & no of securities acquired
Date interest acquired	28 Dec 2017
No of securities	130,745,066
Circumstances by reason of which Securities Holder has interest	Capital Distribution
Nature of interest	Direct Interest
Total no of securities after change
Direct (units)	130,745,066
Direct (%)	46.869
Indirect/deemed interest (units)
Indirect/deemed interest (%)
Date of notice	28 Dec 2017
Date notice received by Listed Issuer	29 Dec 2017

icy97

Notice of Person Ceasing (Section 139 of CA 2016)

CCM DUOPHARMA BIOTECH BERHAD

Particulars of Substantial Securities Holder

Name	CHEMICAL COMPANY OF MALAYSIA BERHAD
Address	13TH FLOOR, MENARA PNB, 201-A JALAN TUN RAZAK, 50400 KUALA LUMPUR KUALA LUMPUR 50400 Wilayah Persekutuan Malaysia.
Company No.	5136-T
Nationality/Country of incorporation	Malaysia
Descriptions (Class)	ORDINARY SHARES
Date of cessation	28 Dec 2017
Name & address of registered holder	CHEMICAL COMPANY OF MALAYSIA BERHAD13TH FLOOR, MENARA PNB, 201-A JALAN TUN RAZAK,50400 KUALA LUMPUR.

No of securities disposed	204,665,784
Circumstances by reason of which a person ceases to be a substantial shareholder	Pursuant to the completion of the capital distribution exercise of 204,665,784 ordinary shares of CCM Duopharma Biotech Berhad ("CCMD") representing 73.37% of the issued capital of CCMD, to the entitled shareholders of Chemical Company of Malaysia Berhad ("CCMB") on 28 December 2017, the direct shareholding of CCMB in CCMD has reduced to 85,824 ordinary shares representing 0.031% of the issued capital of CCMD and therefore CCMB ceased to be a substantial shareholder of CCMD.
Nature of interest	Direct Interest
Date of notice	29 Dec 2017
Date notice received by Listed Issuer	02 Jan 2018

icy97

Name	EMPLOYEES PROVIDENT FUND BOARD
Address	Tingkat 19, Bangunan KWSP, Jalan Raja Laut, 50350 Kuala Lumpur. Kuala Lumpur 50350 Wilayah Persekutuan Malaysia.
Company No.	EPF ACT 1991
Nationality/Country of incorporation	Malaysia
Descriptions (Class)	ORDINARY SHARES
Name & address of registered holder	CITIGROUP NOMINEES (TEMPATAN) SDN. BHD.i) EMPLOYEES PROVIDENT FUND BOARD ii) EMPLOYEES PROVIDENT FUND BOARD (AM INV)iii) EMPLOYEES PROVIDENT FUND BOARD (PHEIM)iv) EMPLOYEES PROVIDENT FUND BOARD (ASIANISLAMIC) ICv) EMPLOYEES PROVIDENT FUND BOARD (ABERISLAMIC) ICLEVEL 42, MENARA CITIBANK, 165 JALAN AMPANG, 50450 KUALA LUMPUR.

Date interest acquired & no of securities acquired
Date interest acquired	29 Dec 2017
No of securities	4,693,258
Circumstances by reason of which Securities Holder has interest	Distribution of Shares on the basis of 1.22 of CCM Duopharma Biotech Berhad's shares for every 1 of Chemical Company of Malaysia Berhad's shares.
Nature of interest	Indirect Interest
Total no of securities after change
Direct (units)
Direct (%)
Indirect/deemed interest (units)	15,997,558
Indirect/deemed interest (%)	5.735
Date of notice	02 Jan 2018
Date notice received by Listed Issuer	03 Jan 2018

icy97

Type	Announcement
Subject	OTHERS
Description	CCM DUOPHARMA BIOTECH BERHAD ("CCMD" OR "THE COMPANY") - FINAL DIVIDEND
The Board of Directors of CCMD is pleased to propose a single-tier final dividend of 6 sen per CCMD Share in respect of the financial year ending 31 December 2017. [The single-tier final dividend is not taxable in the hands of the receiving shareholders.] As CCMD is concurrently proposing to implement a dividend reinvestment plan, the entitlement date, payment date and electable portion of the proposed single-tier final dividend will be announced on a later date. The final dividend, if approved, will be paid no later than 3 months from the date of the shareholders’ approval pursuant to Section 8.26 of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad. This announcement is dated 27 February 2018.

icy97

Type	Announcement
Subject	NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS) COMBINATION OF NEW ISSUE OF SECURITIES
Description	CCM DUOPHARMA BIOTECH BERHAD ("CCMD" OR "THE COMPANY") (I)        PROPOSED BONUS ISSUE; AND(II)        PROPOSED DIVIDEND REINVESTMENT PLAN
On behalf of the Board of Directors of CCMD, UOB Kay Hian Securities (M) Sdn Bhd is pleased to announce that the Company is proposing to undertake the following: (i)        proposed bonus issue of up to 371,945,333 new ordinary shares in CCMD (“CCMD Shares”) (“Bonus Shares”) to be credited as fully paid-up on the basis of 4 Bonus Shares for every 3 existing CCMD Shares held by the shareholders of CCMD at an entitlement date to be determined and announced later (“Proposed Bonus Issue”); and (ii)       establish a dividend reinvestment plan which will provide the Shareholders with an option to elect to reinvest their cash dividend declared by CCMD which includes any interim, final, special or any other cash dividend in CCMD Shares (“Proposed DRP”). (Collectively to be referred to as the Proposals.) Further details on the Proposals are set out in the attachment enclosed. This Announcement is dated 27 February 2018.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/5705089

Attachments CCMD - Proposals.pdf

icy97

Type	Announcement
Subject	OTHERS
Description	CCM DUOPHARMA BIOTECH BERHAD ("CCMD" or "the Company")- Proposed Internal Restructuring
1.         Background The Board of Directors of the Company has approved the following Proposed Internal Restructuring exercise: (i) the acquisition by CCMD of the entire equity interest in CCM Biopharma Sdn Bhd (“CCMBSB”) (a wholly-owned subsidiary of CCMD) and Negeri Pharmacy Sdn Bhd (“NPSB”) (a wholly-owned subsidiary of CCMD) from CCMP (a wholly-owned subsidiary of CCMD) (“Proposed Shares Acquisition I”); (ii) the acquisition by CCMD of the entire equity interest in Upha Pharmaceuticals Manufacturing (M) Sdn Bhd (“UPMSB”) (a wholly subsidiary of CCMD) from DMSB (a wholly-owned subsidiary of CCMD) (“Proposed Shares Acquisition II”); and (iii) the increase of the paid up share capital of UPMSB by way of conversion of a portion of inter-company loan owing by UPMSB to CCMD (“Proposed Conversion”). 2.         Parties to the Proposed Internal Restructuring (i) CCMD is an investment holding and management company with subsidiaries engaged in the manufacturing and marketing of pharmaceuticals products and services and is listed on Bursa Malaysia Securities Berhad. (ii) CCMP is a private company limited by shares and is incorporated in Malaysia. The principal business of CCMP is marketing and sales of medicine and pharmaceutical products. CCMP is a wholly owned subsidiary of the Company. (iii) DMSB is a private company limited by shares and is incorporated in Malaysia. The principal business of DMSB is manufacturing, distribution, importing and exporting of pharmaceutical products and medicines. DMSB is a wholly owned subsidiary of the Company. (iv) CCMBSB is a private company limited by shares and is incorporated in Malaysia. CCMBSB is a dormant company. CCMBSB is a wholly owned subsidiary of CCMP. (v) NPSB is a private company limited by shares and is incorporated in Malaysia.  NPSB is a dormant company. NPSB is a wholly owned subsidiary of CCMP. (vi) UPMSB is a private company limited by shares and is incorporated in Malaysia. The principal business of UPMSB is contract manufacturing of pharmaceutical products and sale of medicines. UPMSB is a wholly owned subsidiary of DMSB. 3.         Details of the Proposed Internal Restructuring (i)         Proposed Shares Acquisition I: Under the Proposed Shares Acquisition I, CCMP shall transfer to CCMD the shares held in CCMBSB and NPSB (“Sale Shares”) free from all charges, liens, encumbrances, equities and claims whatsoever together with all rights attached thereto upon meeting the condition precedents of the share sale agreement in respect of the Proposed Shares Acquisition I. The purchase consideration to be paid by CCMD to CCMP in respect of the transfer of the entire equity interest in CCMBSB and NPSB is RM2,500,000.00 and RM1.00 respectively. The purchase consideration shall be satisfied via cash. In relation to the Proposed Shares Acquisition I, a Share Sale Agreement between CCMP of the one part and CCMD of the other part was executed on 27 February 2018 (“SSA 1”). The summary of the Proposed Shares Acquisition I is set out in Appendix I. (ii) Proposed Shares Acquisition II: Under the Proposed Shares Acquisition II, DMSB shall transfer to CCMD the shares held in UPMSB (“Sale Shares”) free from all charges, liens, encumbrances, equities and claims whatsoever together with all rights attached thereto upon meeting the condition precedents of the share sale agreement in respect of the Proposed Shares Acquisition II. The transfer consideration to be paid by CCMD to DMSB in respect of the transfer of the entire equity interest in UPMSB is RM78, 365,000.00. The transfer consideration shall be satisfied via cash. In relation to the Proposed Shares Acquisition II, a Share Sale Agreement between DMSB of the one part and CCMD of the other part was executed on 27 February 2018 (“SSA 2”). The summary of the Proposed Shares Acquisition II is set out in Appendix I. (iii) Proposed Conversion The Proposed Conversion is expected to reduce the inter-company loan of UPMSB owing to CCMD. The Proposed Conversion will be implemented through the issuance of new ordinary shares of UPMSB to CCMD. In relation to the Proposed Conversion, a Debt Conversion Agreement was executed between CCMD of the one part and UPMSB of the other part on 27 February 2018 (“DCA”). The details of the capitalisation of the amount owing to the Company are set out in Appendix II. 4          Rationale of the Proposed Internal Restructuring The rationale for the Proposed Internal Restructuring is part of CCMD’s effort to streamline its operations to improve management and cost efficiencies. The dormant company may be activated to undertake future projects for the CCMD Group. 5          Effects of the Proposed Internal Restructuring The Proposed Internal Restructuring will not have any material effect on the share capital, shareholding structure, earnings per share and net assets of the Company for the financial year ending 31 December 2018. 6          Approvals Required The Proposed Internal Restructuring is not subject to the approvals of the shareholders of CCMD or the approval of any relevant authorities in Malaysia. The Proposed Internal Restructuring is also subject to approvals being obtained from the relevant financial institutions pursuant to the covenants under the respective facility agreements. 7          Interests of Directors, Major Shareholders and Persons Connected None of the Directors and/or major shareholders or persons connected to them has any interest, direct or indirect in the Proposed Internal Restructuring. 8          Expected Time of Completion of the Proposed Internal Restructuring Barring any unforeseen circumstances, the Proposed Internal Restructuring is expected to be completed in Q2 of 2018. 9          Directors Statement Having considered all aspects of the Proposed Internal Restructuring, the Board of Directors is of the opinion that the Proposed Internal Restructuring is in the best interest of the Company. 10        Documents For Inspection The SSA 1, the SSA 2 and the DCA are available for inspection by the shareholders of the Company at the Registered Office of the Company at 13th Floor, Menara PNB, 201-A, Jalan Tun Razak, 50400 Kuala Lumpur during normal office hours from Mondays to Fridays (except public holidays) for a period of three (3) months commencing from the date of this announcement. This announcement is dated 27 February 2018.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/5705165

Attachments Appendix I - Proposed Internal Restructuring.pdf Appendix II - Proposed Internal Restructuring.pdf

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Dec 2017

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Dec 2017	31 Dec 2016	31 Dec 2017	31 Dec 2016
		$$'000	$$'000	$$'000	$$'000

1	Revenue	112,253	74,033	467,987	312,940
2	Profit/(loss) before tax	12,825	6,299	51,796	31,479
3	Profit/(loss) for the period	11,768	8,831	42,100	26,826
4	Profit/(loss) attributable to ordinary equity holders of the parent	11,870	8,428	42,492	27,115
5	Basic earnings/(loss) per share (Subunit)	4.22	3.41	15.09	9.62
6	Proposed/Declared dividend per share (Subunit)	6.00	4.00	8.50	6.50
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	1.7200		1.6300